Advancements in COVID-19 Treatment Development

Identifying Viral Receptors

In a significant early step towards creating effective treatments for COVID-19, researchers have successfully pinpointed the receptors that enable the virus to penetrate human cells. The urgency for developing treatments or vaccines increases with each new confirmed COVID-19 case. This raises questions about how treatments and vaccines are developed and the reasons behind the lengthy process.

Understanding COVID-19

To formulate an effective therapy for any disease, a thorough understanding of its biology is essential. COVID-19 is the respiratory illness caused by the SARS-CoV-2 virus (previously known as 2019-nCoV). This virus belongs to the Coronaviridae family, which includes enveloped single-stranded RNA viruses that often lead to mild respiratory infections in both humans and animals. A pivotal moment in the study of coronaviruses occurred in 2002 with the emergence of the severe acute respiratory syndrome coronavirus (SARS-CoV) outbreak in Southern China, which resulted in severe illness and fatalities. Both SARS-CoV and SARS-CoV-2 belong to the same family of viruses, indicating their close relationship and shared genetic similarities.

Implications of SARS-CoV Research

The similarities between SARS-CoV and SARS-CoV-2 provide a valuable foundation for scientific inquiry. Understanding the mechanisms of SARS-CoV may shed light on the functioning of SARS-CoV-2. For instance, SARS-CoV utilizes its spike proteins to bind to the ACE2 receptor on host cells, a process crucial for viral entry. Host enzymes, specifically cathepsin L and TMPRSS2, are also essential for the spike protein to successfully fuse with the cellular membrane. Identifying these key proteins is vital, as disrupting their interaction can prevent infection and lead to potential treatments.

Investigating SARS-CoV-2 Entry Mechanisms

Research Findings from Germany

A recent study published in the journal Cell by researchers in Germany explored whether SARS-CoV and SARS-CoV-2 utilize similar mechanisms for cell entry. The team engineered a vesicular stomatitis virus (VSV) to incorporate the spike proteins of both coronaviruses, aiming to determine if these proteins facilitated infection in the same cell types. The results indicated that both spike proteins allowed entry into similar cell types, implying that they might use analogous receptors to access target cells.

Role of ACE2 in Virus Entry

The researchers further analyzed the amino acid sequences of the spike proteins and confirmed that the residues responsible for interacting with the ACE2 receptor were present in both proteins. They conducted experiments using BHK-21 cells, which were genetically modified to express human or bat ACE2 proteins. These modified cells became susceptible to infection by viruses containing either SARS-CoV or SARS-CoV-2 spike proteins. Additionally, authentic SARS-CoV-2 virus infections yielded similar results, confirming ACE2 as the receptor for SARS-CoV-2.

Enzyme Assistance in Viral Entry

The study also investigated whether SARS-CoV-2 requires enzymes for cell entry, similar to SARS-CoV’s reliance on cathepsin L. Researchers treated two cell lines with ammonium chloride to inhibit cathepsin L activity, which resulted in blocked viral entry, indicating the enzyme’s necessity for SARS-CoV-2 entry. Subsequently, they applied camostat mesylate, a TMPRSS2 inhibitor, and found it partially impeded viral entry for SARS-CoV-2 spike protein viruses. Further analysis showed that camostat mesylate treatment also prevented SARS-CoV-2 from entering lung cell lines and patient-derived lung cells, confirming that SARS-CoV-2 employs both cathepsin L and TMPRSS2 for cell entry.

Future Directions and Considerations

Implications for Treatment

While the findings of this study are promising, several factors warrant attention. Many experiments utilized VSV instead of SARS-CoV-2, necessitating further validation with the actual virus. The authors suggest that camostat mesylate could serve as a potential therapeutic candidate, as it blocked viral entry and is already approved for clinical use in Japan for chronic pancreatitis. However, a new clinical trial would be essential to assess its efficacy and safety for COVID-19 patients.

Challenges Ahead

It is important to note that inhibiting TMPRSS2 alone may not be sufficient to entirely prevent SARS-CoV-2 infection and transmission. Although the research represents progress, it was conducted in laboratory settings. Any new potential therapeutic agents for COVID-19 treatment would require extensive animal studies and clinical trials before receiving approval from regulatory agencies like the FDA or EMA, which could take years.

Current Prevention Measures

Given the ongoing challenges, adhering to preventative measures remains crucial. Following WHO guidelines, such as frequent handwashing, covering coughs and sneezes, avoiding face-touching, and maintaining social distance, can significantly reduce the risk of COVID-19 infection.

Author Information

Written by Tarryn Bourhill, MSc, PhD Candidate.

References

1. Dong E, D. H., Gardner L. Wuhan Coronavirus (2019-nCoV) Global Cases (2020).
2. Simmons, G., Zmora, P., Gierer, S., Heurich, A. & Pöhlmann, S. Proteolytic activation of the SARS-coronavirus spike protein: cutting enzymes at the cutting edge of antiviral research. Antiviral research 100, 605-614 (2013).
3. Sahin, A. R. et al. 2019 Novel Coronavirus (COVID-19) Outbreak: A Review of the Current Literature. EJMO 4, 1-7 (2020).
4. Zhang, H., Penninger, J. M., Li, Y., Zhong, N. & Slutsky, A. S. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Medicine, 1-5 (2020).
5. Chhikara, B. S., Rathi, B., Singh, J. & Poonam, F. Coronavirus SARS-CoV-2 disease COVID-19: Infection, prevention and clinical advances of the prospective chemical drug therapeutics. Chemical Biology Letters 7, 63-72 (2020).
6. Hoffmann, M. et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell (2020).
7. Organisation, W. H. Coronavirus disease (COVID-19) advice for the public, (2020).